Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). (Q47798072)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). |
scientific article |
Statements
1 reference
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). (English)
1 reference
1 reference
K Yamazaki
1 reference
M Nagase
1 reference
H Tamagawa
1 reference
S Ueda
1 reference
T Tamura
1 reference
K Murata
1 reference
T Eguchi Nakajima
1 reference
E Baba
1 reference
M Tsuda
1 reference
T Moriwaki
1 reference
T Esaki
1 reference
Y Tsuji
1 reference
K Muro
1 reference
K Taira
1 reference
T Denda
1 reference
S Funai
1 reference
K Shinozaki
1 reference
H Yamashita
1 reference
N Sugimoto
1 reference
T Okuno
1 reference
T Nishina
1 reference
M Umeki
1 reference
T Kurimoto
1 reference
T Takayama
1 reference
A Tsuji
1 reference
M Yoshida
1 reference
A Hosokawa
1 reference
Y Shibata
1 reference
K Suyama
1 reference
M Okabe
1 reference
K Suzuki
1 reference
N Seki
1 reference
K Kawakami
1 reference
M Sato
1 reference
K Fujikawa
1 reference
T Hirashima
1 reference
K Taku
1 reference
T Otsuji
1 reference
F Tamura
1 reference
E Shinozaki
1 reference
K Nakashima
1 reference
H Hara
1 reference
T Tsushima
1 reference
M Ando
1 reference
S Morita
1 reference
N Boku
1 reference
I Hyodo
1 reference
13 May 2016
1 reference
27
1 reference
8
1 reference
1539-1546
1 reference